Activity Overview
This online, on-demand virtual symposium brings together renowned experts in neovascular retinal diseases, including nAMD and DME. In this educational program, these experts use a case-based format to discuss the latest data regarding effective management of these disorders, share their perspectives and best practices, and forecast applications of key clinical challenges and questions.
This educational activity is an archive of the live virtual symposium held on February 17, 2026.
Target Audience
This educational activity is directed toward ophthalmologists, optometrists, and other eye care professionals involved in the management of nAMD and DME patients.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Summarize the real-world safety and efficacy of anti-VEGF intravitreal injection therapies for nAMD and DME.
- Implement novel therapies in the management of nAMD and DME.
- Apply multidisciplinary, patient-centered approaches that facilitate timely care coordination in patients with nAMD and DME.
Murtaza K. Adam, MD, FASRS
Partner
Physician
Chair
of Clinical Research
Colorado
Retina Associates
Denver,
CO
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: 4DMT, AbbVie, Alkeus, Apellis, Dutch Ophthalmic Research Center, Genentech, Iveric Bio (an Astellas Company), Neurotech, NorthGauge Healthcare Advisors, Regeneron, Regenxbio; Speakers Bureau: Amgen, Apellis, Genentech/Roche, Iveric Bio (an Astellas Company), Regeneron; Grant/Research Funding: 4DMT, AbbVie, EyeBio, EyePoint, Genentech, Regeneron, Regenxbio; Ownership Interests in Privately Held Companies: Lumata Health, Sanro Health
Deepak Sambhara, MD, FASRS
Adjunct
Assistant Professor
Medical
College of Wisconsin
Partner,
Medical Director of Research
Eye
Clinic of Wisconsin
Wausau,
WI
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: 4DMT, AbbVie, Adverum, Alcon, Alkeus, Annexon, ANI, Apellis, Astellas, EyePoint, Genentech, Heidelberg Engineering, Kodiak, Ocular Therapeutix, Opthea, Regeneron, Topcon; Grant/Research Funding: 4DMT, Adverum, Annexon, Kodiak, Ocular Therapeutix; Ownership Interests in Privately Held Companies: Eclipse Life Sciences, RevOpsis
Betty Zhang, OD
Colorado
Retina Associates
Denver,
CO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Apellis
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
